NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy
Open Access
- 3 January 2020
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (3) , 1762-1771
Abstract
The pathological hallmark of synucleinopathies, including Lewy body dementia and Parkinson’s disease (PD), is the presence of Lewy bodies, which are primarily composed of intracellular inclusions of misfolded α-synuclein (α-syn) among other proteins. α-Syn is found in extracellular biological fluids in PD patients and has been implicated in modulating immune responses in the central nervous system (CNS) and the periphery. Natural killer (NK) cells are innate effector lymphocytes that are present in the CNS in homeostatic and pathological conditions. NK cell numbers are increased in the blood of PD patients and their activity is associated with disease severity; however, the role of NK cells in the context of α-synucleinopathies has never been explored. Here, we show that human NK cells can efficiently internalize and degrade α-syn aggregates via the endosomal/lysosomal pathway. We demonstrate that α-syn aggregates attenuate NK cell cytotoxicity in a dose-dependent manner and decrease the release of the proinflammatory cytokine, IFN-γ. To address the role of NK cells in PD pathogenesis, NK cell function was investigated in a preformed fibril α-syn–induced mouse PD model. Our studies demonstrate that in vivo depletion of NK cells in a preclinical mouse PD model resulted in exacerbated motor deficits and increased phosphorylated α-syn deposits. Collectively, our data provide a role of NK cells in modulating synuclein pathology and motor symptoms in a preclinical mouse model of PD, which could be developed into a therapeutic for PD and other synucleinopathies.Keywords
Funding Information
- UGA | College of Veterinary Medicine, University of Georgia (Physiology and Pharmacology start-up)
- Michael J. Fox Foundation for Parkinson's Research (Target Validation grant)
- Georgia Partners in Regenerative Medicine (Seed Grant)
This publication has 76 references indexed in Scilit:
- Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survivalOncoImmunology, 2016
- Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microgliaNature Communications, 2013
- Toll‐like receptor 4 is required for α‐synuclein dependent activation of microglia and astrogliaGlia, 2012
- Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-SynucleinJournal of Neuroimmune Pharmacology, 2012
- Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in miceJournal of Experimental Medicine, 2012
- FimH Can Directly Activate Human and Murine Natural Killer Cells via TLR4Molecular Therapy, 2010
- Direct TLR2 Signaling Is Critical for NK Cell Activation and Function in Response to Vaccinia Viral InfectionPLOS Pathogens, 2010
- NK Cells Play a Critical Protective Role in Host Defense against Acute Extracellular Staphylococcus aureus Bacterial Infection in the LungThe Journal of Immunology, 2008
- Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's diseaseThe FASEB Journal, 2006
- A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament AssemblyJournal of Biological Chemistry, 2001